1. Introduction {#s0005}
===============

Vitiligo, an idiopathic skin depigmentation disorder, is caused by the destruction of melanocytes from the basal layer of the epidermis as a result of which irregularly shaped milky white patches appear on the lesional skin ([@bb0125]). Vitiligo affects approximately 1% of the world population including both men and women unbiasedly from all ethnicities ([@bb0140]). Although, it is not a life threatening disorder but this could be psychologically devastating leading to mild embarrassment to a severe loss of self-confidence for the affected person especially the dark skinned people because of the presence of white patches on the skin ([@bb0100]).

Melanocytes are solely responsible for the melanin pigment production by the process named melanogenesis which imparts color to the skin. Loss of melanocyte results in lack of melanin and thus, milky white patches appear at the lesion site. The exact pathophysiology of vitiligo is hard to pin down but various theories based on autoimmunity ([@bb0035], [@bb0070]), oxidative stress ([@bb0020]), neural factors ([@bb0090]) and genetic defects ([@bb0125]) have been proposed to explain the reason of melanocyte destruction. Various researchers are focusing their efforts to explicate the mechanism of skin pigmentation and its regulation with the purpose of better management of pigmentary disorder. More than 150 genes are identified that affect pigmentation in skin, hair and eye along with multiple transcription factors, signaling factors and other biological factors involved in its regulatory pathway known to interfere with pigmentation process ([@bb0005]). Candidate gene association studies have reported more than 33 genes involved in generalized vitiligo ([@bb0130]).

Liver X Receptor (LXR) is ligand (such as oxysterol, high concentration of [d]{.smallcaps}-glucose) activated nuclear transcription factor which regulate the expression of target genes involved in various physiological processes. LXR exists in two isoforms: LXR-α and LXR-β. LXR-α is highly expressed in several metabolically active tissues including liver, adipose tissue, macrophages, and intestine, whereas LXR-β is ubiquitously expressed in most tissues ([@bb0135], [@bb0030], [@bb0075]). Recently, LXR has also been shown to express in skin tissue such as sebaceous gland, hair follicle, epidermal keratinocyte and fibroblast and was found to be linked with various skin disorder pathogeneses like psoriasis and acne vulgaris ([@bb0115]). Melanocytes express LXR but the functions of LXR in these cells are still elusive ([@bb0065]).

Kumar et al. observed high expression of LXR-α at both transcriptional and translational levels in the melanocytes obtained from perilesional skin compared to the normal skin of vitiligo patient ([@bb0065]). The involvement of LXR-α in the development of vitiligo. Various researchers have reported the effect of activated LXR on melanogenesis ([@bb0065], [@bb0075]). Kumar et al. further showed that LXR-α agonist 22(R)-hydroxycholesterol treatment significantly downregulates the cell adhesion molecule, suggesting the existence of melanocytorrhagy in which melanocytes with defective adhesion system induces detachment from the basement membrane in perilesional vitiligo skin followed by melanocyte apoptosis ([@bb0050]). Lei et al. demonstrated that matrix metalloproteinase 2 (MMP 2) plays an important role in melanoblast (melanocyte precursor) migration from the outer root sheath of hair follicle into clinically depigmented epidermis and crucial for the repigmentation of vitiliginous skin ([@bb0085]). But, the study by Kumar et al. reported that MMP-2 and MMP-9 were downregulated in vitiligo patient and furthermore, it was shown that LXR-α gene knock-down significantly increased the expression of MMPs ([@bb0055]). Recently, Lee et al. reported that the activated LXR inhibits the melanogenesis through the accelerated activation of extracellular signal-regulated kinase (ERK) mediated microphthalmia-associated transcription factor (MITF) degradation ([@bb0075]). Thus, upregulated expression of LXR-α in perilesional skin melanocytes significantly decreases the adhesion, proliferation and matrix metalloproteinases and increases apoptosis. Based on all these studies, LXRs appear to play a key role in vitiligo pathogenesis and considered as a potential therapeutic target for vitiligo ([@bb0060]). Variation in gene expression which is considered as an intrinsic factor in a disease may be associated with both genetic factor (mutational changes, single nucleotide polymorphism, epigenetic change) and non-genetic factors (level of agonists e.g. oxysterol, drugs such as statins, fibrates, thazolidinedione derivatives, level of antagonists e.g. oxysterol sulfonates).

We selected two LXR-α single nucleotide polymorphisms (SNPs; rs11039155 and rs2279238) to investigate their contribution to the risk of vitiligo. These SNPs have been reported to be associated with many metabolic indicators and conditions, including circulating LDL and HDL-cholesterol concentrations ([@bb0110]; Sabatti et al., 2009), type 2 diabetes mellitus ([@bb0010], [@bb0040]) and obesity ([@bb0015]). To the best of our knowledge, this is the first study to assess the association of LXR-α polymorphisms with vitiligo disorder.

2. Material and methods {#s0010}
=======================

2.1. Study population {#s0015}
---------------------

The studied group included 66 vitiligo patients (27 females/39 males; mean age: 27.38 ± 14.06) attending in Department of Dermatology, Dr. Rajendra Prasad Government Medical College, Kangra, Himachal Pradesh and Dr. Bansal\'s Skin Laser Center Clinic, Manimajra, Chandigarh. The diagnosis of vitiligo was established using standard diagnostic criteria. Clinical history of vitiligo and any other autoimmune disease in patients was taken by clinical interview. A total of 75 (31 females/44 males) healthy individuals with no history of vitiligo or apparent autoimmune disease were included as control; they matched to patients with regard to age, sex and geographical distribution. The study was approved by Institutional Ethical Committees of Dr. Rajendra Prasad Government Medical College and Jaypee University of Information Technology, Solan, Himachal Pradesh. The importance of the study was explained to all participants and written consent was obtained from patients and controls.

2.2. Sampling, DNA isolation and genotyping {#s0020}
-------------------------------------------

Peripheral blood (2 ml) was collected from the patients and healthy subjects in Na~2~EDTA coated tubes. Genomic DNA was extracted from peripheral blood using a standard salting out procedure described earlier ([@bb0095]).

Genotyping of LXR-α − 6 G \> A and + 1257 C \> T SNP was done using the polymerase chain reaction-restriction fragment length polymorphism (PCR-RFLP) method as described earlier ([@bb0080], [@bb0025]). Briefly, the DNA fragments containing these SNPs were amplified in 25 μl reaction mixture containing 12.5 μl PCR master mix (Promega, Madison, US), 0.2 μM of each primer and 40 ng of DNA template. The primer pairs used were, for − 6G \> A (Forward 5′-GTG AGA GGA TCA CTT GAG C-3′ and Reverse 5′-CAG ACC GCA GGC TCC ACG C-3′; amplifies 366 bp fragment), and for + 1257C \> T (Forward 5′-CTT TCT GAG CCT CAC TTT CC-3′ and Reverse 5′-CGC AGC TCA GAA CAT TGT AG-3′; amplifies 377 bp fragment). The PCR amplification conditions were: 3 min initial denaturation at 94 °C, followed by 35 cycles of denaturation at 94 °C for 30 s, annealing for − 6G \> A for 30 s at 62 °C & for + 1257C \> T for 45 s at 60 °C and 30 s of extension at 72 °C followed by final extension at 72 °C for 5 min. Amplified PCR products were analyzed on 1.5% agarose gel by ethidium bromide staining. For RFLP analysis, PCR products were digested with 1 U of respective restriction enzyme (Hpy188III for − 6G \> A and Fnu4HI for + 1257C \> T) for 4 h at 37 °C. Digested products were analyzed on 3% agarose gel containing ethidium bromide.

2.3. Statistical analysis {#s0025}
-------------------------

Allelic and genotypic frequencies were calculated using Microsoft Excel software (Microsoft Corporation). Hardy--Weinberg equilibrium (HWE) was tested to determine if the population fulfilled the HWE at the variant locus. The observed genotype distribution of control was assessed for deviation from HWE using a chi square test (<http://www.had2know.com/academics/hardy-weinberg-equilibrium-calculator-2-alleles.html>). Odds ratios and 95% confidence intervals were calculated to assess the risk associated with alleles and genotype. RevMan v5.3 was used to calculate odds ratio. The significance of the odds ratio was determined by Z test (p \< 0.05 was considered statistically significant).

3. Results {#s0030}
==========

Clinical and demographic characteristics of vitiligo patients are shown in [Table 1](#t0005){ref-type="table"}. The average ages of patients and controls were 27.38 ± 14.06 yr and 23.05 ± 7.08 yr, respectively. The average age at onset of disease was 18.09 ± 10.44 yr. The majority of patients (75%) had less than 25% body coverage of the depigmented patches.

Patient and control subjects were genotyped applying PCR-RFLP assay for − 6G \> A and + 1257C \> T in LXR-α gene. The genotypes and allele frequencies of LXR-α polymorphisms (rs11039155 and rs2279238) in patients and controls are summarized in [Table 2](#t0010){ref-type="table"}. The genotype distribution for both the SNP showed no deviation from Hardy--Weinberg equilibrium in control population (p \> 0.05). Genotyping of the SNPs in the LXR-α gene revealed that the allele A of rs11039155 was found in 13% of controls and 24% of patients; the allele T of rs2279238 was found in 47% of controls and 60% of patients. Both of the alleles − 6A and + 1257T were found to increase the risk of vitiligo (rs11039155: odds ratio (OR) = 1.99; 95% confidence interval (CI) = 1.07--3.71; rs2279238: OR = 1.70; 95% CI = 1.06--2.73) implicating that these SNPs could be a prognostic marker for the disease. Dominant and co-dominant models of rs11039155 ([Table 3](#t0015){ref-type="table"}) demonstrate that the presence of A allele in the individual\'s genotype predisposes that person to the vitiligo. Recessive and homozygous models of rs2279238 demonstrate that allele T is associated with the vitiligo susceptibility.

4. Discussion {#s0035}
=============

Vitiligo is a multifactorial complex genetic disorder leading to skin depigmentation ([@bb0125]). It has been reported that variations in the genes could affect their stability, expression or regulation which might account for disease susceptibility in the patients. Identification of these potential vitiligo susceptibility variants would lead to better understanding of disease pathogenesis and targeted disease treatment.

Recent reports have shown that Liver X Receptor, an inducible transcription factor, plays an important role in vitiligo pathogenesis. Genes involved in regulation of melanocytes are the target genes of LXRs ([@bb0055], [@bb0050], [@bb0060]). Although the exact role of LXR-α in development of vitiligo is not known, a number of reports have demonstrated higher expression of LXR-α in the melanocytes obtained from perilesional skin of the vitiligo patient which speculates its role in vitiligo pathogenesis ([@bb0065]),([@bb0060], [@bb0075]). In the present study, we have investigated vitiligo patients for genetic variation in the LXR-α gene. We focused on SNPs rs2279238 (+ 1257 C \> T) and rs11039155 (− 6 G \> A) in LXR-α gene to assess their involvement in the susceptibility to vitiligo in North Indian population. Various studies have reported association of these SNPs with high levels of circulating LDL and HDL-cholesterol ([@bb0110], [@bb0080], [@bb0120]), type 2 diabetes mellitus ([@bb0010], [@bb0040]) and obesity ([@bb0015]). To the best of our knowledge, this is the first report showing association of LXR-α variants with the risk of vitiligo. Our data suggested that − 6A and + 1257T alleles were significantly associated with the risk of vitiligo.

These polymorphic markers may contribute to changes in expression of LXR-α in vitiligo. The − 6 G \> A polymorphism is located six base pairs upstream from the ATG site and is part of Kozak sequence could affect translation efficiency of a gene. This sequence in the LXR-α gene (**GA**AGAG[**ATG**]{.ul}T) is different from the consensus Kozak sequence (**GA**CACC[**ATG**]{.ul}G). Moreover, polymorphism/change of G at − 6 position to A may alter translation efficiency of this gene ([@bb0045], [@bb0080]).

Second SNP, + 1257C \> T is located at an exon splicing enhancer (ESE) of LXR-α where splicing factor SRp55 binds. This polymorphic marker can affect mRNA splicing, stability and translation efficiency (due to codon usage) ([@bb0105]). However, in-depth molecular studies are required to elucidate the functional roles of the rs11039155 and rs2279238 for an understanding of its role in vitiligo which could guide the development of new ligands for the treatment of vitiligo. Furthermore, these SNPs could be in linkage disequilibrium with another SNPs affecting LXR-α expression. The present study had few limitations. First, sample size was small which contributes to low statistical power. Secondly, lack of knowledge about the functional influence of the identified polymorphisms with vitiligo remains to be determined.

In conclusion, variant − 6 A and + 1257 T alleles of LXR-α were significantly associated with the risk of vitiligo in North Indian population and underscore the importance of genetic factors in vitiligo pathogenesis. However, studies with large number of samples as well as from other populations are needed to further validate these findings. These data provide support for additional prospective studies since LXR-α is an inducible transcription factor. Further studies elucidating the role of other functional SNPs of LXR-α and other related genes involved in related biological pathways that are involved in the etiology of vitiligo would be useful. In addition to this, studies elucidating the role of these SNPs in the treatment response would be helpful for the better management of this disease.
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###### 

Clinical and demographic characteristics of vitiligo cases and control group.

  Characteristics                                   Vitiligo (N = 66)   Controls (N = 75)
  ------------------------------------------------- ------------------- -------------------
  Sex (n/N \[%\])                                                       
   Female                                           27/66 \[41\]        31/75 \[41\]
   Male                                             39/66 \[59\]        44/75 \[59\]
  Age                                               27.38 ± 14.06 yr    23.05 ± 7.08 yr
  Age at the onset                                  18.09 ± 10.44 yr    
  Changing size of depigmented patches (n/N\[%\])   40/60 \[67\]        
  Body coverage of depigmented patches (%)                              
   1--25                                            75                  
   26--50                                           5                   
   51--75                                           9                   
   76--100                                          11                  
  Reported family history of vitiligo (n/N \[%\])   5/66 \[7\]          

###### 

Genotypes and alleles frequencies distribution of the Liver X Receptor-α polymorphism in vitiligo cases (N = 66) and control (N = 75). Bold represents statistical significant odds ratio.

  Genotype/allele           Vitiligo (n/N \[%\])   Control (n/N \[%\])   p-Value     Odds ratio \[95% CI\]     HWE p-value
  ------------------------- ---------------------- --------------------- ----------- ------------------------- -------------
  rs11039155 (− 6 G \> A)                                                                                      
  Genotype                                                                                                     
   GG                       35/66 \[53\]           55/75 \[73\]                                                0.183
   GA                       31/66 \[47\]           20/75 \[27\]                                                
   AA                       0                      0                                                           
  Allele                                                                                                       
   G                        101/132 \[76\]         130/150 \[87\]        **0.03**    **1.99 \[1.07--3.71\]**   
   A                        31/132 \[24\]          20/150 \[13\]                                               
                                                                                                               
  rs2279238 (C \> T)                                                                                           
  Genotype                                                                                                     
   CC                       9/66 \[14\]            19/75 \[25\]                                                0.279
   CT                       35/66 \[53\]           42/75 \[56\]                                                
   TT                       22/66 \[33\]           14/75 \[19\]                                                
  Allele                                                                                                       
   C                        53/132 \[40\]          80/150 \[53\]         **0.027**   **1.70 \[1.06--2.73\]**   
   T                        79/132 \[60\]          70/150 \[47\]                                               

###### 

Association between LXR-α polymorphism and vitiligo susceptibility. Bold represents statistical significant odds ratio.

  Polymorphism model                Odds ratio      95% CI            p-Value
  --------------------------------- --------------- ----------------- -----------
  *rs11039155*                                                        
  Dominant model (AA + GA vs GG)    **2.43**        **1.20--4.92**    **0.013**
  Recessive model (AA vs GA + GG)   Not estimable                     
  Homozygous model (AA vs GG)       Not estimable                     
  Co-dominant model (GA vs GG)      **2.43**        **1.20--4.92**    **0.013**
                                                                      
  *rs2279238*                                                         
  Dominant model (CT + TT vs CC)    2.15            0.89--5.15        0.080
  Recessive model (TT vs CT + CC)   **2.17**        **1.004--4.72**   **0.048**
  Homozygous model (TT vs CC)       **3.30**        **1.17--9.37**    **0.020**
  Co-dominant model (CT vs CC)      1.75            0.70--4.37        0.220
